Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.03.029
Abstract: OBJECTIVES SMARCA4-deficient thoracic sarcoma(DTS) is a recently identified new entity of thoracic malignancies characterized by inactivation of SMARCA4. Patients with SMARCA4-DTS have a particulary aggresive clinical course and no effective treatments. However, the detailed clinical… read more here.
Keywords: deficient thoracic; smarca4; patients smarca4; thoracic sarcoma ... See more keywords
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00662
Abstract: Bromodomains are acetyllysine recognition domains present in a variety of human proteins. Bromodomains also bind small molecules that compete with acetyllysine, and therefore bromodomains have been targets for drug discovery efforts. Highly potent and selective… read more here.
Keywords: bromodomains smarca2; smarca4; gne 064; pbrm1 ... See more keywords
Novel SMARCA4 Variant in an Infant With Atypical Teratoid Rhabdoid Tumor
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000003004
Abstract: Atypical teratoid/rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors. Typically, AT/RT is classified as SMARCB1 (INI-1) deficient or as SMARCA4 (BRG1) deficient. In this case, we describe a unique case of AT/RT with… read more here.
Keywords: variant; atypical teratoid; smarca4; teratoid rhabdoid ... See more keywords
80 Smarca4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-igcs.80
Abstract: Objectives A rare subset of aggressive SMARCA4-deficient uterine sarcomas (SMARCA4-DUS) has been recently proposed, with only a limited number of cases having been previously described. Since potential targeted therapies exist for SMARCA4-defficient tumors, we sought… read more here.
Keywords: smarca4 dus; small cell; uterine sarcomas; smarca4 ... See more keywords
Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/0008-5472.can-24-0044
Abstract: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4. read more here.
Keywords: loss; intron retention; smarca4; leads intron ... See more keywords
Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/0008-5472.can-24-2054
Abstract: Epigenetic reprogramming in SMARCA4-mutant cancer cells alters immune infiltration and limits immunotherapy efficacy by downregulating immunostimulatory gene expression, which could potentially be targeted to overcome immunotherapy resistance in SMARCA4-deficient tumors. read more here.
Keywords: cancer; resistance; smarca4 induces; immunotherapy ... See more keywords
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
Sign Up to like & getrecommendations! Published in 2025 at "Cancer research"
DOI: 10.1158/0008-5472.can-25-1141
Abstract: SMARCA2 and SMARCA4 are the core catalytic subunits of the SWI/SNF chromatin remodeling complex. Approximately 10% of non-small cell lung cancer (NSCLC) patients harbor SMARCA4 mutations, resulting in protein loss or loss-of-function (LOF) alterations. These… read more here.
Keywords: smarca2; mutated cancers; smarca4; prt3789 ... See more keywords
Abstract C025: Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-25-c025
Abstract: The BAF (SWI/SNF) chromatin remodelling complex comprises two mutually exclusive ATP-dependent helicase subunits, SMARCA2 (BRM) and SMARCA4 (BRG1), which regulate chromatin architecture by mobilizing and repositioning nucleosomes on DNA. This activity is critical for various… read more here.
Keywords: smarca4; degrader; smarca4 mutant; orally bio ... See more keywords
Abstract 2577: Pre-cancerous ovarian cells harboring a familial SMARCA4 mutation acquire in vitro phenotypes associated with transformation in SSCOHT
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2577
Abstract: Introduction: Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT) is an extremely rare but deadly ovarian cancer associated with mutations in the SMARCA4 gene. Using a unique population of ovarian cells derived from a… read more here.
Keywords: smarca4; ovarian cells; smarca4 mutation; p583 cells ... See more keywords
Abstract 6277: Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4- deficient solid tumor
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6277
Abstract: Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to target previously undruggable targets. However, it has been more challenging to identify orally bioavailable TPD molecules due to the physicochemical properties of… read more here.
Keywords: smarca2; orally bioavailable; smarca4 deficient; smarca4 ... See more keywords
Abstract 3304: Modulation of enhancer accessibility by SMARCA2 PROTACs synergize with TEAD inhibitors to suppress growth of SMARCA4 mutant lung cancers
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-3304
Abstract: The SWI/SNF chromatin remodeling complex is frequently mutated in non-small cell lung cancer with a frequency of 33% in advanced stage disease, making it the most commonly altered complex in lung cancer. Among the various… read more here.
Keywords: cancer; lung; smarca4; smarca4 mutant ... See more keywords